Results 221 to 230 of about 133,463 (299)

Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development. [PDF]

Pharmaceuticals (Basel)
Li L, Li J, Yang L, Zhou J, Ma Y.
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium. [PDF]

J Neurooncol
Damante MA, Juncker RB, Little AS, Van Gompel JJ, Palit S, Pacione DR, Barkhoudarian G, Sivakumar W, Blackburn S, Mendoza MM, Evans JJ, Benjamin C, Palmer JD, Giglio P, Prevedello DM, Wu KC, RAPID Consortium.   +16 more
europepmc   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

British Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang, Hio Lam Ho, F. David Horgen, Andrea Fleig, Zhong‐Ping Feng, Hong‐Shuo Sun   +5 more
wiley   +1 more source

Targeting Hippo-MAPK crosstalk in schwannoma: Overcoming resistance with dual inhibition. [PDF]

Mol Ther Oncol
Chen Z, Zhao L, Shipman T, Wang Y, McKay RM, Chen L, Le LQ.   +6 more
europepmc   +1 more source

MEK Inhibitor PD0325901 [PDF]

, 2020
openaire   +1 more source

Interaction with NEGR1 affects mGlu5 cell signalling and the neuroprotection induced by the positive allosteric modulator VU0409551

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The metabotropic glutamate receptor mGlu5 plays an important role in neuronal survival and synaptic plasticity. We and others have shown that mGlu5 positive allosteric modulators (PAMs) are biased agonists, triggering the activation of neuroprotective pathways and promoting neuronal survival. As mGlu5 biased pharmacology
Jennifer D. S. Guimaraes, Toniana G. Carvalho, Luan A. Pereira, Emanuele G. Silva, Esther M. A. Maciel, Gabriella P. Torres, Thiago Assis, Pablo L. Cardozo, Joao P. P. de Almeida, Nathalia C. Silva, Francesca Pischedda, Giovanni Piccoli, Luciene B. Vieira, Juliana Alves‐Silva, Fabiola M. Ribeiro   +14 more
wiley   +1 more source

Dietary melatonin and its benefits on cardiovascular disease

British Journal of Pharmacology, EarlyView.
Cardiovascular disease remains the leading cause of mortality globally, with a disproportionate burden in low‐ and middle‐income countries. Melatonin, a hormone primarily produced by the pineal gland, exhibits notable antioxidant, anti‐inflammatory and immunomodulatory properties that may confer cardiovascular benefits.
Karabo Tisane, Carmelita Abrahams, Sandrine Lecour   +2 more
wiley   +1 more source

MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. [PDF]

Oncologist
Auckley ED, Yohay S, Ying G, Szabo A, Wittmann J, Grahl J, Aldakkak M, Thalji SZ, McFall T, Kurzrock R, George B, Kamgar M.   +11 more
europepmc   +1 more source

Enhancement of the leptomeninges in a young man

Brain Pathology, EarlyView.
Jayden Ray, Mohammad Alberawi, Andrew Bauer, Kar‐Ming Fung, Erika Santos Horta, Lorraina J. Robinson   +5 more
wiley   +1 more source